RecruitingPHASE1, PHASE2NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Studying Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
- Intervention
- MDX2001(drug)
- Enrollment
- 115 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (6)
- Sarah Cannon Research Institute, Denver, Colorado, United States
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- NEXT Oncology, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06239194 on ClinicalTrials.govOther trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06990659Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)University Hospital, Angers
- RECRUITINGPHASE2NCT07146646Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06529718Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsUNICANCER
- RECRUITINGNCT07151118ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerCHA University
- RECRUITINGNCT07142226Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCCHA University
- RECRUITINGPHASE2NCT07135544A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract CancerYongjun Chen
- RECRUITINGNCT06793709A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyEisai Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06708663HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid TumoursHangzhou Hanx Biopharmaceuticals, Ltd.
See all trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract →